x

Join Advarra

Learn more about our company team, careers, and values. Join Advarra’s Talented team to take on engaging work in a dynamic environment.

See Jobs

 
Blog

Most Popular Blogs of 2019

What did the research community enjoy most in 2019? Read Advarra's most popular blogs from industry experts and IRB members here.

Read Now
2 min. read
Read more
 
Blog

Reporting to the IRB: What NOT to Report

Reportable events can be tricky: according to the regulations, not every unanticipated event should be submitted to the IRB.

Read Now
6 min. read
Read more
 
Blog

Making Sense of the New HUD Guidance

Understand how the new HUD guidance clarifies responsibilites of the IRB and institutions, while widening the access of small communities to HUDs.

Read Now
7 min. read
Read more
 
Blog

Should Social Media Be Part of Your Research Toolbox?

Social media has emerged as a valuable tool for diverse stakeholders across the research community. Learn about the risks and benefits in this article.

Read Now
5 min. read
Read more
 
Blog

A Tale of Two Sites: The Power of Integrated Research Administration

Learn how institutions attract more studies from the the tale of two sites: one with an integrated research administration, and one without.

Read Now
5 min. read
Read more
 
Blog

Reporting to the IRB: Unanticipated Device Effects in Medical Device Studies

What do the regulations say about unanticipated device effects and IRB reporting? In this blog, Advarra addresses unique requirements for medical device studies.

Read Now
2 min. read
Read more
 
Blog

Advarra Acquires Forte:
What You Need to Know

On September 5, 2019, Advarra announced its intent to acquire Forte.

Read Now
Read more
 
Blog

Compensating Clinical Trial Participants: The Basics

Participant compensation is often a complicated matter. This blog will shed light on what an IRB considers during its review.

Read Now
5 min. read
Read more
 
Blog

What Is a Screening Consent?

Study-specific screening consent is a subtype of informed consent, which ensures a research participant understands of the research and its risks.

Read Now
3 min. read
Read more
 
Blog

Quality Improvement Project vs Human Subject Research: What’s the Difference?

Quality improvement and human subjects research often intersect. Executive IRB Chair Sara Harnish discusses questions to differentiate the two.

Read Now
3 min. read
Read more
 
Blog

The Future of Phase I Oncology Studies

Oncology drugs in phase I trials are usually conducted on patients with cancer due to their inherent risk. Advarra IRB member Ran Goldman expands:

Read Now
4 min. read
Read more
 
Blog

Meeting the Challenges of Investigator-Initiated Trials

How does investigator-initiated research differ from other types of clinical research? Advarra IRB Chairperson Robert Romanchuk explains.

Read Now
6 min. read
Read more